Paper32268367
Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
Stiekema LCA and 11 others. Eur Heart J, 2020. Cited by 94 papers, by iCite.
Cite this record
ConductScience Library. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Papers, record 32268367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32268367
- Disease
- cardiovascular disorder522 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lipoprotein(a) | Major topic |
| Monocytes | Major topic |
| Apoprotein(a) | |
| Humans | |
| Oligonucleotides | |
| Proprotein Convertase 9 |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02729025 | Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03070782 | Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease | Derived from the trial | Yes | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 32445566 | Mechanistic insights into lipoprotein(a): from infamous to 'inflammous'. | https://conductscience.org/library/papers/32445566 |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18423196 | Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. | Cell | 2008 | https://conductscience.org/library/papers/18423196 | PubMed |
| 2 | 30561610 | Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. | Eur Heart J | 2019 | https://conductscience.org/library/papers/30561610 | PubMed |
| 3 | 9077376 | Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. | N Engl J Med | 1997 | https://conductscience.org/library/papers/9077376 | PubMed |
| 4 | 24333007 | Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. | Metabolism | 2014 | https://conductscience.org/library/papers/24333007 | PubMed |
| 5 | 29926099 | Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. | JAMA Cardiol | 2018 | https://conductscience.org/library/papers/29926099 | PubMed |
| 6 | 20706656 | DAMPening inflammation by modulating TLR signalling. | Mediators Inflamm | 2010 | https://conductscience.org/library/papers/20706656 | PubMed |
| 7 | 28845751 | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28845751 | PubMed |
| 8 | 27764724 | Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. | Atherosclerosis | 2016 | https://conductscience.org/library/papers/27764724 | PubMed |
| 9 | 12432042 | Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. | N Engl J Med | 2002 | https://conductscience.org/library/papers/12432042 | PubMed |
| 10 | 20032323 | Genetic variants associated with Lp(a) lipoprotein level and coronary disease. | N Engl J Med | 2009 | https://conductscience.org/library/papers/20032323 | PubMed |
| 11 | 23727083 | Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. | J Am Coll Cardiol | 2013 | https://conductscience.org/library/papers/23727083 | PubMed |
| 12 | 27496857 | Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. | Circulation | 2016 | https://conductscience.org/library/papers/27496857 | PubMed |
| 13 | 25014686 | Effects of extended-release niacin with laropiprant in high-risk patients. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25014686 | PubMed |
| 14 | 30293769 | Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. | Lancet | 2018 | https://conductscience.org/library/papers/30293769 | PubMed |
| 15 | 17981204 | Regulation of interferon-gamma during innate and adaptive immune responses. | Adv Immunol | 2007 | https://conductscience.org/library/papers/17981204 | PubMed |
| 16 | 28183512 | A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. | J Am Coll Cardiol | 2017 | https://conductscience.org/library/papers/28183512 | PubMed |
| 17 | 29875409 | Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. | Nature | 2018 | https://conductscience.org/library/papers/29875409 | PubMed |
| 18 | 27665230 | Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. | Lancet | 2016 | https://conductscience.org/library/papers/27665230 | PubMed |
| 19 | 19509380 | Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. | JAMA | 2009 | https://conductscience.org/library/papers/19509380 | PubMed |
| 20 | 28329114 | PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. | Eur Heart J | 2017 | https://conductscience.org/library/papers/28329114 | PubMed |
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42878985 | GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases. | Curr Atheroscler Rep | 2026 | https://conductscience.org/library/papers/42878985 | PubMed |
| 42814209 | The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps. | Curr Atheroscler Rep | 2026 | https://conductscience.org/library/papers/42814209 | PubMed |
| 42693289 | Genetic evidence supports the combined targeting of lipoprotein(a) and LDL cholesterol to reduce coronary artery disease risk. | Nat Cardiovasc Res | 2026 | https://conductscience.org/library/papers/42693289 | PubMed |
| 41538799 | Beyond lipids: Systemic effects of lipoprotein apheresis. | Transfusion | 2026 | https://conductscience.org/library/papers/41538799 | PubMed |
| 41488100 | Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41488100 | PubMed |
| 41264184 | Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies. | Cardiovasc Drugs Ther | 2026 | https://conductscience.org/library/papers/41264184 | PubMed |
| 41217319 | Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. | J Am Coll Cardiol | 2025 | https://conductscience.org/library/papers/41217319 | PubMed |
| 41103683 | Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis. | Biochem Med (Zagreb) | 2025 | https://conductscience.org/library/papers/41103683 | PubMed |
| 41054423 | Monocytes from people with Familial Hypercholesterolaemia are inflammatory, despite statin-treatment. | Atheroscler Plus | 2025 | https://conductscience.org/library/papers/41054423 | PubMed |
| 40757148 | Lipoprotein (a) in primary cardiovascular disease prevention is actionable today. | Am Heart J Plus | 2025 | https://conductscience.org/library/papers/40757148 | PubMed |
| 40682836 | Research advances in current drugs targeting hyperlipidemia (Review). | Mol Med Rep | 2025 | https://conductscience.org/library/papers/40682836 | PubMed |
| 40574736 | Prognostic value of lymphocyte-to-monocyte ratio in patients with endometrial cancer: an updated systematic review and meta-analysis. | PeerJ | 2025 | https://conductscience.org/library/papers/40574736 | PubMed |
| 40334781 | Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease. | J Lipid Res | 2025 | https://conductscience.org/library/papers/40334781 | PubMed |
| 40322720 | Lipoprotein(a)-Lowering Drugs: A Mini Review. | J Clin Med Res | 2025 | https://conductscience.org/library/papers/40322720 | PubMed |
| 40004172 | The Interplay Between Immunity, Inflammation and Endothelial Dysfunction. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004172 | PubMed |
| 39959304 | Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/39959304 | PubMed |
| 39934244 | Development and validation of a predictive model for carotid atherosclerosis in postmenopausal women. | Sci Rep | 2025 | https://conductscience.org/library/papers/39934244 | PubMed |
| 39912915 | Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study. | Clin Res Cardiol | 2025 | https://conductscience.org/library/papers/39912915 | PubMed |
| 39289929 | Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/39289929 | PubMed |
| 39031302 | Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review. | Cardiol Ther | 2024 | https://conductscience.org/library/papers/39031302 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| EVOLOCUMAB | CHEMBL2364655 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2364655 | ChEMBL |
| PELACARSEN | CHEMBL4298202 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4298202 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32268367
GET https://conductscience.org/api/papers/v1/32268367/references?page=2